Traws Pharma Announces Positive Data For Anti-Viral Candidate Tivoxavir Marboxil In Bird Flu Model

(RTTNews) - Traws Pharma, Inc. (TRAW), Monday announced positive topline results from ferrets infected with H5N1 bird flu treated with tivoxavir marboxil as a single dose.

The study, conducted using a the A/Texas/37/2024 H5N1 virus isolated from an infected dairy worker in Texas, showed suppression of disease, with reduced viral burden in lungs and nasal tissue.

The company intends to conduct a similar challenge study in non-human primates, with data expected in Q1 2025.

CEO Werner Cautreels said that the company intends to approach the FDA, along with the non-human primate data in hand, to discuss an accelerated approval under to the 'Animal Rule'.

Currently, Traws's stock is trading at $2.9, down 12.39 percent on the Nasdaq.